Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,744 total articles
NextEra Energy's pullback is a buying opportunity. The stock trades near $86 with a 2.76% yield, a 52-week range of $69.24-$98.75 and a market cap of ~$179.2B. Growing large-load demand from AI data centers, a meaningful renewables backlog and steady regulated utility cash flows support upside to near-term resistance around $98. This trade idea out…
BHP has been pigeonholed as an iron ore miner for years. That narrative is outdated. With large-scale copper exposure, the ramp of Jansen potash, and exploration moves in Africa, BHP looks set to re-rate. Technical momentum and a still-attractive yield make a structured long trade compelling over the next 45 trading days.
Energy Transfer (ET) offers a compelling entry: buy units at $21.17 for a roughly 6.4% yield on cost, backed by raised 2026 guidance, expanding infrastructure exposure to AI data centers and LNG exports, and an 8.2x EV/EBITDA valuation. Target $24.50 over the next 180 trading days while protecting capital with a $19.00 stop.
Arista posted a $3.036B Q2 and raised guidance to $12.6B, validating its AI networking momentum. Strong margins, $5.16B in free cash flow and zero debt underpin a thesis for multiple expansion. Initiate a long with a $186.46 entry, $240 target and $160 stop for a long-term (180 trading days) trade.
Infosys is trading near its recent lows after a sharp re-rating, but fundamentals and strategic M&A suggest the market has overshot. At $12.03 the stock offers a 3.8% yield, a P/E around 14.5, and an attractive market-cap base of $48.8B. We recommend a disciplined long with a defined entry at $12.00, stop at $10.25 and target of $16.50 over a swing…
Seabridge Gold is a development-stage gold company with sizable long-life projects and a capital structure that can deliver big upside if permitting, financing or a major partner materializes. The stock looks fairly priced for the base case but offers an attractive asymmetric payoff if catalysts hit. This trade idea lays out a concrete entry, prote…
Hanmi Financial (HAFC) is showing steady earnings power, a conservative balance sheet and active capital returns. At roughly $31.15, the shares look positioned for a mid-term re-rating supported by continued buybacks, a raised dividend and low leverage. This trade idea lays out entry, target and stop along with the catalysts and risks that will det…
Trevi Therapeutics (TRVI) is a clinical-stage biotech advancing Haduvio (oral nalbuphine ER) for chronic cough and pruritic conditions. Recent financing and conference activity have tightened the runway and investor attention; valuation is rich given development-stage fundamentals, but positive cough data and heavy short interest create a tacticall…
ServiceNow is positioned to report another AI-accelerated quarter. With a $29B backlog, $4.6B in free cash flow and improving technical momentum, the pieces point to a Q3 beat. This is a tactical swing long: enter at market, limit risk with a $115 stop, target $150 as investors re-rate durable AI workflow monetization.
Frontline plc (FRO) looks expensive to some screens - price near a 52-week high and elevated PB - but dividend yield (7.2%), improving tanker fundamentals and bullish momentum create a compelling mid-term trade. Entry $44.43, stop $39.00, target $52.00; mid-term (45 trading days) outlook.
Meta's shares have retraced sharply from last year's peak as a major child safety trial and broader market risk-off sentiment weigh on the name. At $550 today, the company still generates robust free cash flow ($40.98B) and trades at ~20x earnings, leaving room for upside if ad demand stabilizes and litigation proves containable. This note lays out…
PayPal’s board rejected a $60.50-per-share joint offer from Stripe and Advent International. With a $52B+ market cap, strong free cash flow and a low multiple profile, PayPal is an attractive takeover target that could prompt a renewed bid above the current $61 area. This note lays out an actionable trade: enter at $61.35, target $70.00, stop $58.0…
SK hynix sits at the intersection of secular AI memory demand and a highly consolidated supply base. For disciplined traders willing to tolerate memory cyclicality, a controlled long-term long can capture significant upside if industry economics and M&A dynamics accelerate.
Himax (HIMX) is a small-cap semiconductor specialist that quietly supplies display drivers, wafer-level optics and LCoS microdisplays into automotive and AR chains. The business combines in-house manufacturing, steady cash return via dividends, and recent product ramps (OLED touch controllers, Front-lit LCoS) that justify a tactical long. We lay ou…
Teradyne is benefiting from an AI-led memory and semiconductor cycle that is pushing test volume and complexity higher. Strong Q2 results and bullish guidance justify an upgraded buy, but near-term volatility and stretched multiples argue for a dip-entry approach. Trade plan included for a mid-term swing with clear entry, stop and target.
Elanco's recent quarterly beat, new emergency-use approvals, and continued pet-care tailwinds create a practical long trade with clearly defined entry, stop and target. The company trades at roughly $12.2B market cap, generates positive free cash flow, and carries moderate leverage - a setup where execution on product launches will control the next…
UiPath has moved from growth skepticism to hitting profitability, raising guidance and showing early success with agentic AI orchestration. With a market cap near $8.2B, attractive cash flow, improving margins and heavy short positioning, the risk/reward favors a tactical long over the next 45 trading days if ARR and execution continue to validate …
Sensata Technologies is a sensor and electrical-protection specialist showing clear operational cash-generation and addressable-market tailwinds from EVs, charging infrastructure, and industrial electrification. The stock is trading below key moving averages with an attractive free-cash-flow yield versus peers; this trade targets a mid-term re-rati…
Journey Medical's Q2 narrative and commercial update show Emrosi gaining prescription traction despite reimbursement timing noise. At a $192M market cap, improving script flow, falling short interest and bullish technicals create a favorable risk/reward for a mid-term long trade. This idea includes a clear entry at $6.81, a $9.25 target and a $5.25…
LightPath Technologies is increasingly relevant to Western defense and commercial optics supply chains. The company's infrared and thermal optics wins, low leverage, and recently strengthened balance sheet set up a tactical long. We lay out an actionable swing trade with clear entry, target and stop, plus the catalysts and risks that will move the …
Alphabet looks like a classic compounding machine: dominant cash-generating core, an expanding AI moat, and a long-term buyer in Berkshire Hathaway reinforcing the narrative. The valuation and balance sheet give room for patient, structured exposure. This trade idea lays out an actionable plan with entry, stop, and target and explains why the risk/…
Genesco is showing the kind of operating resilience and cash generation that justifies upgrading the stock. Revenue growth at the Journeys division, a clean balance sheet, and low EV/EBITDA and price-to-book multiples give a favorable risk-reward. This trade plan targets a move toward the 52-week high while keeping a disciplined stop.
Rivian's early R2 sales and Q2 margin improvement give the company a clearer path to profitability. With a market cap near $22.8B, improving software and services margins, and meaningful liquidity commitments, this trade favors a long on a measured pullback. Entry at $15.00, stop at $13.50, target at $22.00 over a mid-term (45 trading days) horizon…
Blue Owl (OWL) looks set to extend a multi-week rebound. The alternative asset manager generates meaningful free cash flow, supports a high distribution yield, and has seen short interest ease — a combination that can fuel a mid-term rally. Trade plan: enter at $11.78, target $14.72, stop $10.20. Horizon: mid term (45 trading days).
Travere Therapeutics has run hard from its 52-week low, but its $6.2B market cap and $6.5B enterprise value still leave room for gains if its rare-disease franchise and pipeline continue to convert. Momentum is healthy, free cash flow is positive, and short interest plus activist/legal noise create both downside risk and upside fuel. I outline an a…
